NOVATO, Calif. — November 4, 2025 — Leads & Copy — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has announced the sale of an additional 25% of its royalty interest from Kyowa Kirin Co., Ltd on future Crysvita sales in the U.S. and Canada to OMERS for $400 million.
OMERS will receive the additional royalty interest beginning in January 2028. The total payments to OMERS are capped at 1.55 times the purchase price.
According to Ultragenyx, the cash will bolster its balance sheet to help deliver on expected launches and achieve full-year GAAP profitability in 2027. The company CFO Howard Horn stated that OMERS offered the most attractive financial package.
Rob Missere from OMERS noted that the deal aligns with their life sciences investment strategy and mandate of delivering long-term returns to its members.
TD Cowen acted as the financial advisor for Ultragenyx, and Gibson, Dunn, & Crutcher LLP was the legal advisor. Davies Ward Phillips & Vineberg LLP, Latham & Watkins LLP, and Sidley Austin LLP were legal advisors to OMERS.
Ultragenyx is focused on therapies for rare and ultra-rare genetic diseases. Crysvita was developed and commercialized through a collaboration between Kyowa Kirin and Ultragenyx.
Joshua Higa, ir@ultragenyx.com
Jess Rowlands, media@ultragenyx.com
Don Peat, 416-417-7385, dpeat@omers.com
Source: Ultragenyx Pharmaceutical Inc.
